Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6406 to 6420 of 8908 results

  1. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued Reference number: GID-TAG363

    Technology appraisal guidance
    Discontinued

  2. Constipation (opioid induced) - lubiprostone [ID646]

    Discontinued Reference number: GID-TAG367

    Technology appraisal guidance
    Discontinued

  3. Multiple sclerosis - sativex [ID387]

    Discontinued Reference number: GID-TAG368

    Technology appraisal guidance
    Discontinued

  4. New pharmaceutical treatments for non-Alzheimer dementias [ID380]

    Discontinued Reference number: GID-TAG369

    Technology appraisal guidance
    Discontinued

  5. Venous leg ulcers - new treatments [ID394]

    Discontinued Reference number: GID-TAG370

    Technology appraisal guidance
    Discontinued

  6. Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]

    Discontinued Reference number: GID-TA10585

    Technology appraisal guidance
    Discontinued

  7. Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

    In development Reference number: GID-TA10589 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

    Discontinued Reference number: GID-TA10590

    Technology appraisal guidance
    Discontinued

  9. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued Reference number: GID-TA10591

    Technology appraisal guidance
    Discontinued

  10. Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]

    In development Reference number: GID-TA10592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

    In development Reference number: GID-TA10598 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Omburtamab for treating relapsed neuroblastoma [ID1664]

    In development Reference number: GID-TA10608 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

    Discontinued Reference number: GID-TA10609

    Technology appraisal guidance
    Discontinued

  14. Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]

    Discontinued Reference number: GID-TA10616

    Technology appraisal guidance
    Discontinued

  15. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]

    Discontinued Reference number: GID-TA10617

    Technology appraisal guidance
    Discontinued